var data={"title":"Ifosfamide: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ifosfamide: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6355?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ifosfamide-drug-information\" class=\"drug drug_general\">see &quot;Ifosfamide: Drug information&quot;</a> and <a href=\"topic.htm?path=ifosfamide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ifosfamide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708917\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bone marrow suppression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Myelosuppression can be severe and lead to fatal infections. Monitor blood counts prior to and at intervals after each treatment cycle.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">CNS toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">CNS toxicities can be severe and result in encephalopathy and death. Monitor for CNS toxicity and discontinue treatment for encephalopathy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hemorrhagic cystitis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Hemorrhagic cystitis can be severe and can be reduced by the prophylactic use of mesna.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Nephrotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Nephrotoxicity can be severe and result in renal failure.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181779\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ifex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181780\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ifex;</li>\n      <li>Ifosfamide for Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047814\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Alkylating Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047806\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ifosfamide-drug-information\" class=\"drug drug_general\">see &quot;Ifosfamide: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> To prevent bladder toxicity, combination therapy with mesna (bladder protectant or chemoprotectant) and hydration in adults and pediatric patients is necessary; in adults, at least 2 L/day of oral or IV fluid. In pediatric patients, specific protocols should be consulted for hydration recommendation; for example, some centers have used 2 times maintenance or 3 L/m<sup>2</sup>/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dosing may be based on either BSA (mg/m<sup>2</sup>) or weight (mg/<b>kg</b>); use extra precautions to verify dosing parameters during calculations. Protocol-specific details concerning dosing, frequency, and combination regimens should be consulted. Ifosfamide is associated with a moderate emetic potential (Dupuis 2011); antiemetics are recommended to prevent nausea and vomiting (Dupuis 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ewing sarcoma:</b> Limited data available; dosing regimens and combinations variable: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IE regimen: IV: 1,800 mg/m<sup>2</sup> over 1 hour once daily  for 5 days in combination with mesna and etoposide every 3 weeks for 12 cycles; or may alternate with VAC (vincristine, doxorubicin, and cyclophosphamide) every 3 weeks for a total of 17 courses (Grier 2003; Miser 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HD-IE regimen: 2,800 mg/m<sup>2</sup> over 1 hour once daily for 5 days in combination with mesna and etoposide every 3 weeks alternating with VAC (vincristine, doxorubicin, cyclophosphamide) (Miser 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ICE regimen: IV: 1,800 mg/m<sup>2</sup> once daily for 5 days every 3 to 4 weeks for up to 12 cycles in combination with carboplatin, etoposide, and mesna; or may follow with 2 courses of CAV (cyclophosphamide, doxorubicin, and vincristine) (Milano 2006; van Winkle 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">VAIA regimen: Reported dosing variable: IV: 3,000 mg/m<sup>2</sup>  on days 1, 2, 22, 23, 43, and 44 for 4 courses in combination with vincristine, doxorubicin, dactinomycin, and mesna (Paulussen 2001) <b>or</b> 2,000 mg/m<sup>2</sup> once daily for 3 days every 3 weeks for 14 courses in combination with vincristine, doxorubicin, and dactinomycin (Paulussen 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">VIDE regimen: IV: 3,000 mg/m<sup>2</sup> over 1 to 3 hours once daily for 3 days every 3 weeks for 6 courses in combination with vincristine, doxorubicin, etoposide, and mesna (Juergens 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lymphoma, Hodgkin (HL) and Non-Hodgkin (NHL), recurrent/refractory:</b> Limited data available; dosing regimens and combinations variable:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ICE regimen:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Cairo 2005:</i> Children and Adolescents: IV: 1,800 mg/m<sup>2</sup> once daily for 5 days every 3 weeks for 6 courses in combination with etoposide, carboplatin, and mesna; in the trial, although the minimum age for inclusion was 1 year of age, the reported patient age range was 8 months to 26 years (median: 10.5 years)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Moskowitz 2001:</i> Children &ge;12 years and Adolescents: IV: 5,000 mg/m<sup>2</sup>/day continuous infusion over 24 hours beginning on day 2 every 2 weeks for 2 cycles (in combination with mesna, carboplatin, and etoposide)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IE regimen: Children and Adolescents: IV: 1,800 mg/m<sup>2</sup> once daily for 5 days alternating in combination with etoposide and mesna; alternate at 3-week intervals with DECAL (dexamethasone, etoposide, cisplatin, cytarabine [high-dose ara-C]), and L-asparaginase for 4 cycles; in the trial, all patients were &lt;21 years of age, the median age for NHL: 11 years; median age for HL: 15 years (Kobrinsky 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">MIED regimen: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Sandlund 2011:</i> IV: 2,000 mg/m<sup>2</sup> over 2 hours on days 2 to 4 in combination with high-dose methotrexate, etoposide, and dexamethasone (and mesna); patients with NHL also received intrathecal methotrexate, hydrocortisone, and cytarabine</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Griffin 2009:</i> IV: 3,000 mg/m<sup>2</sup> over 2 hours on days 3 to 5 in combination with rituximab and ICE (carboplatin, etoposide, and mensa) every 23 days for up to 3 courses has been used in NHL patients</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteosarcoma:</b> Limited data available; dosing regimens and combinations variable:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IE regimen: Children and Adolescents: IV: 1,800 to 3,000 mg/m<sup>2</sup> for 4 to 5 days; frequency and duration protocol specific with etoposide and mesna (Gentet 1997; Marina 2016; O&rsquo;Kane 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ICE regimen: Children and Adolescents: IV: 1,800 mg/m<sup>2</sup> once daily for 5 days every 3 weeks for up to 12 cycles in combination with carboplatin, etoposide, and mesna (van Winkle 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Newly diagnosed high-grade osteosarcoma of the extremity with metastases:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i> Bacci 2003</i>:  Children and Adolescents: IV: 3,000 mg/m<sup>2</sup>/day continuous infusion for 5 days (total dose: 15 g/m<sup>2</sup>) during weeks 4 and 10 (preop) and during weeks 16, 25, and 34 (postop) in combination with cisplatin, doxorubicin, methotrexate (high-dose), and mesna</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i> Basaran 2007</i>: Adolescents: IV: 2,000 mg/m<sup>2</sup> over 4 hours for 3 days (days 2, 3, and 4) every 3 weeks for 3 cycles (preop) and every 4 weeks for 3 cycles (postop) in combination with cisplatin, epirubicin, and mesna</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i> Le Deley 2007</i>: Children and Adolescents: IV: 3,000 mg/m<sup>2</sup> over 3 hours for 4 days during weeks 4 and 9 (three additional postop courses were administered in good responders) in combination with methotrexate (high-dose), etoposide, and mesna</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neuroblastoma, refractory or relapsed: </b>Limited data available: HD-ICE regimen: Children and Adolescents IV:  2,000 mg/m<sup>2 </sup>over 2 hours once daily for 5 days in combination with mesna, carboplatin, and etoposide with or without peripheral blood stem cell support (depending on hematologic reserve (Kushner 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rhabdomyosarcoma: </b>Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Interval-compressed I/E regimen (Weigel 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: IV:  900 mg/m<sup>2</sup> once daily for 5 days in combination with mesna and etoposide on weeks 9, 13, 17, 26, and 30 (2 weeks after vincristine, doxorubicin, and cyclophosphamide therapy). <b>Note:</b> Infant dose is 50% of full dose in children; if infant tolerates dose (ie, no delayed count recovery or delayed resolution of other toxicities which delays administration), may consider increasing to 75% and then to 100% calculated full dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents: IV: 1,800 mg/m<sup>2</sup> once daily for 5 days in combination with mesna and etoposide on weeks 9, 13, 17, and 30 (2 weeks after vincristine, doxorubicin, and cyclophosphamide therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">VAI (IRS-IV) (Baker 2000):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: IV: 900 mg/m<sup>2</sup> once daily for 5 days in combination with mesna, vincristine, and dactinomycin for a 21-day cycle for 8 cycles (omitting dactinomycin during radiation).<b> Note:</b> Infant dose is 50% of full-dose in children; if infant tolerates dose (ie, no delayed count recovery or delayed resolution of other toxicities which delays administration), may consider increasing to 75% and then to 100% calculated full dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents: IV: 1,800 mg/m<sup>2</sup> once daily for 5 days in combination with mesna, vincristine, and dactinomycin for a 21-day cycle for 8 cycles (omitting dactinomycin during radiation)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">VIE (IRS-IV; Baker 2000):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: IV: 900 mg/m<sup>2</sup> once daily for 5 days in combination with mesna, vincristine, and etoposide  for a 21-day cycle for 8 cycles (omitting etoposide during radiation).<b> Note:</b> Infant dose is 50% of full-dose in children; if infant tolerates dose (ie, no delayed count recovery or delayed resolution of other toxicities which delays administration), may consider increasing to 75% and then to 100% calculated full dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents: IV: 1,800 mg/m<sup>2</sup> once daily for 5 days in combination with mesna, vincristine, and etoposide for a 21-day cycle for 8 cycles (omitting etoposide during radiation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sarcomas; soft tissue, non-Rhabdomyosarcoma: </b>Limited data available: Children and Adolescents: 3,000 mg/m<sup>2</sup> once daily for 3 days every 21 days for 4 cycles in combination with mesna and doxorubicin (Ferrari 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Wilms tumor, relapsed: </b>Limited data available: ICE regimen: Children and Adolescents: IV: 1,800 mg/m<sup>2</sup> once daily for 5 days every 21 days for at least 2  cycles (median of 4 cycles reported) in combination with mesna, carboplatin, and etoposide (Abu-Ghosh 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Testicular cancer:</b> IV: 1,200 mg/m<sup>2</sup>/day for 5 days in combination with other chemotherapy agents and mesna every 3 weeks or after hematologic recovery</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustments in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: The following adjustments have been recommended (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &ge;10 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: 1,000 mg/m<sup>2</sup> followed by hemodialysis 6 to 8 hours later</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Manufacturer's labeling: Consider dosage reduction in patients with renal impairment; however, there are no dosage adjustments provided in the manufacturer's labeling; ifosfamide (and metabolites) are excreted renally and may accumulate in patients with renal dysfunction. Ifosfamide and metabolites are dialyzable.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The following adjustments have been recommended:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Aronoff 2007:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &ge;10 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;10 mL/minute: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hemodialysis: No supplemental dose needed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Kintzel 1995:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &gt;60 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 46 to 60 mL/minute: Administer 80% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 31 to 45 mL/minute: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &le;30 mL/minute: Administer 70% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustments in hepatic impairment:</b> Adults: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, ifosfamide is extensively metabolized in the liver to both active and inactive metabolites; use with caution. The following adjustments have been recommended (Floyd 2006): Bilirubin &gt;3 mg/dL: Administer 25% of dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181758\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g/20 mL (20 mL); 3 g/60 mL (60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g/20 mL (20 mL); 3 g/60 mL (60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ifex: 1 g (1 ea); 3 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea); 3 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181743\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047818\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Ifosfamide is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Basch 2011; Dupuis 2011; Roila 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer as a slow IV intermittent infusion or continuous infusion; infusion times may vary by protocol; in adults, usually over at least 30 minutes; in pediatric trials, infusion time varied; doses usually infused  over  1 to 6 hours or administered as a 24-hour infusion; refer to specific protocols.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132621\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181773\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials of powder for injection at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); avoid temperatures &gt;30&deg;C (86&deg;F). Store intact vials of solution at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Reconstituted solutions and solutions diluted in D5W, NS, or LR for administration are stable for 24 hours refrigerated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047817\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of germ cell testicular cancer in combination with other antineoplastic agents (FDA approved in adults); <b>Note:</b> Should be used in combination with mesna for prophylaxis of hemorrhagic cystitis; has also been used in the treatment of Hodgkin and non-Hodgkin lymphoma, Ewing sarcoma, osteosarcoma, neuroblastoma, rhabdomyosarcoma, and soft tissue sarcomas</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2136825\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ifosfamide may be confused with cyclophosphamide</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181833\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Localized phlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Brain disease, central nervous system toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia (more common with combination therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Metabolic acidosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, febrile neutropenia, leukopenia (nadir: 8 to 14 days), thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic insufficiency, increased serum bilirubin, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Hematuria (reduced with mesna), renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abdominal pain, abnormal gait, acute renal failure, agranulocytosis, altered hormone level (increased gonadotropin), amenorrhea, amnesia, anaphylaxis, angina pectoris, angioedema, anovulation, anuria, arthralgia, asterixis, atrial premature contractions, atrial fibrillation, atrial flutter, atrial premature contractions, azoospermia, blood coagulation disorder, blurred vision, bone marrow failure, bradycardia, bradyphrenia, bronchospasm, bundle branch block, capillary leak syndrome, cardiac arrhythmia, cardiac failure, cardiogenic shock, cardiomyopathy, cardiotoxicity, casts in urine, catatonia, chest pain, chills, cholestasis, chronic renal failure, colitis, conjunctivitis, constipation, cough, increased serum creatinine, decreased creatinine clearance, decreased plasma estrogen concentration, deep vein thrombosis, delirium, delusions, dermatitis, diarrhea, disseminated intravascular coagulation, dysarthria, dysesthesia, dyspnea, dysuria, ECG abnormality (QRS complex abnormal), edema, enterocolitis, erythema, extrapyramidal reaction, facial swelling, Fanconi&rsquo;s syndrome, fatigue, fecal incontinence, flushing, fulminant hepatitis, gastrointestinal hemorrhage, glycosuria, granulocytopenia, growth suppression (children), hearing loss, hemolytic anemia, hemolytic-uremic syndrome, hemorrhage (including myocardial), hemorrhagic cystitis, hepatic failure, hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease), hepatitis (cytolytic), hepatorenal syndrome, herpes zoster, hyperglycemia, hyperhidrosis, hypertension, hyperpigmentation, hypersensitivity pneumonitis, hypersensitivity reaction, hypocalcemia, hypoesthesia, hypokalemia, hyponatremia, hypophosphatemia, hypotension, hypoxia, intestinal obstruction, immunosuppression, increased blood urea nitrogen, increased creatinine clearance, increased gamma-glutamyl transferase, increased lactate dehydrogenase, increased serum alkaline phosphatase, infertility, infusion site reaction (erythema, inflammation, pain, pruritus, swelling, tenderness), inhibition of spermatogenesis, interstitial nephritis, interstitial pneumonitis, interstitial pulmonary disease, inversion T wave on ECG, irritable bladder, jaundice, left ventricular dysfunction (failure), leukoencephalopathy, limb pain, lymphocytopenia, malaise, mania, menopause (premature), mental status changes, metastases (including ALL, AML, APL, lymphoma, MDS, RCC, sarcomas, thyroid cancer), methemoglobinemia, mucosal inflammation, mucous membrane ulceration, multi-organ failure, muscle twitching, mutism, myalgia, myocardial infarction, myocarditis, nail disease, nephrogenic diabetes insipidus, neuralgia, neutropenia, oligospermia, oliguria, osteomalacia (adults), ovarian failure, pain, palmar-plantar erythrodysesthesia, pancreatitis, pancytopenia, panic attack, paranoia, parenchymal damage (renal), paresthesia, pericardial effusion, pericarditis, peripheral neuropathy, petechia, phosphaturia, physical health deterioration, pleural effusion, pneumonia (including <i>Pneumocystis jirovecii</i>), pneumonitis, pollakiuria, polydipsia, polyneuropathy, polyuria, portal vein thrombosis, progressive multifocal leukoencephalopathy, proteinuria, pruritus, pulmonary edema, pulmonary embolism, pulmonary fibrosis, pulmonary hypertension, reduced ejection fraction, renal tubular acidosis, renal tubular necrosis, respiratory distress syndrome (acute), respiratory failure, reversible posterior leukoencephalopathy syndrome, rhabdomyolysis, rickets, salivation, seizure, sepsis, septic shock, SIADH, skin abnormalities related to radiation recall, skin necrosis, skin rash (including macular and papular), status epilepticus, sterility, Stevens-Johnson syndrome, stomatitis, ST segment changes on ECG, supraventricular extrasystole, tachycardia, talkativeness (logorrhea), tinnitus, toxic epidermal necrolysis, tumor lysis syndrome, typhlitis, uremia, urinary incontinence, urine abnormality (aminoaciduria and enzymuria), urticaria, vasculitis, ventricular fibrillation, ventricular premature contractions, ventricular tachycardia, vertigo, viral hepatitis, visual impairment, wound healing impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181764\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Known hypersensitivity to ifosfamide or any component of the formulation; urinary outflow obstruction </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Severe leukopenia/thrombocytopenia; severe renal and/or hepatic impairment; cystitis; active infection; advanced cerebral arteriosclerosis </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181747\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b>[US Boxed Warning]: Bone marrow suppression may occur (may be severe and lead to fatal infections); monitor blood counts before and after each cycle.</b> Leukopenia, neutropenia, thrombocytopenia, and anemia are associated with ifosfamide. Myelosuppression is dose dependent, increased with single high doses (compared to fractionated doses) and increased with decreased renal function. Severe myelosuppression may occur when administered in combination with other chemotherapy agents or radiation therapy. Use with caution in patients with compromised bone marrow reserve. Unless clinically necessary, avoid administering to patients with WBC &lt;2,000/mm<sup>3</sup> and platelets &lt;50,000/mm<sup>3</sup>. Bleeding events due to thrombocytopenia may occur. Antimicrobial prophylaxis may be necessary in some neutropenic patients; administer antibiotics and/or antifungal agents for neutropenic fever.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiotoxicity: Ifosfamide-induced cardiotoxicity has been reported; may be fatal. Arrhythmias (eg, atrial/supraventricular tachycardia, atrial fibrillation, pulseless ventricular tachycardia), ST-segment or T-wave changes, cardiomyopathy, pericardial effusion, pericarditis, and epicardial fibrosis have been observed. The risk for cardiotoxicity is dose-dependent; concomitant cardiotoxic agents (eg, anthracyclines), irradiation of the cardiac region, and renal impairment may also increase the risk. Use with caution in patients with cardiac risk factors or pre-existing cardiac disease. In a scientific statement from the American Heart Association, ifosfamide has been determined to be an agent that may either cause reversible direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate/major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS toxicity: <b>[US Boxed Warning]: May cause CNS toxicity which may be severe, resulting in encephalopathy and death; monitor for CNS toxicity; discontinue for encephalopathy.</b> Symptoms of CNS toxicity (somnolence, confusion, dizziness, disorientation, hallucinations, cranial nerve dysfunction, psychotic behavior, extrapyramidal symptoms, seizures, coma, peripheral neuropathy, blurred vision, and/or urinary incontinence) have been observed within a few hours to a few days after initial dose, and generally resolve within 2 to 3 days of treatment discontinuation (although symptoms may persist longer); maintain supportive care until complete resolution. Recurrence of CNS toxicity (after several cycles with no CNS incidents) has been reported. Risk factors for CNS toxicity may include hypoalbuminemia, renal dysfunction, and high-dose antiemetic therapy. Concomitant centrally-acting medications may result in additive CNS effects. Peripheral neuropathy has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Ifosfamide is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011; Hesketh 2017; Roila 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemorrhagic cystitis: <b>[US Boxed Warning]: Hemorrhagic cystitis may occur (may be severe); concomitant mesna reduces the risk of hemorrhagic cystitis.</b> Hydration (at least 2 L/day in adults), dose fractionation, and/or mesna administration will reduce the incidence of hematuria and protect against hemorrhagic cystitis. Obtain urinalysis prior to each dose; if microscopic hematuria is detected, withhold until complete resolution. Exclude or correct urinary tract obstructions prior to treatment. Use with caution (if at all) in patients with active urinary tract infection. Hemorrhagic cystitis is dose-dependent and is increased with high single doses (compared with fractionated doses); past or concomitant bladder radiation or busulfan treatment may increase the risk for hemorrhagic cystitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Hepatic sinusoidal obstruction syndrome (SOS), formerly called veno-occlusive disease (VOD), has been reported with ifosfamide-containing regimens.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions have been associated with ifosfamide. Cross sensitivity with similar agents may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: May cause significant suppression of the immune responses; may lead to serious infection, sepsis or septic shock. Reported infections have included bacterial, viral, fungal, and parasitic; latent viral infections may be reactivated. Use with caution with other immunosuppressants or in patients with infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: Interstitial pneumonitis, pulmonary fibrosis, and pulmonary toxicity leading to respiratory failure (may be fatal) have been reported. Monitor for signs and symptoms of pulmonary toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal toxicity: <b>[US Boxed Warning]: May cause severe nephrotoxicity, resulting in renal failure.</b> Nephrotoxicity may be fatal. Acute and chronic renal failure, as well as renal parenchymal and tubular necrosis (including acute), have been reported; tubular damage may be delayed (months to years) and may persist. Renal manifestations include decreased glomerular rate, increased creatinine, proteinuria, enzymuria, cylindruria, tubular acidosis, aminoaciduria, phosphaturia, and glycosuria. Syndrome of inappropriate antidiuretic hormone (SIADH), renal rickets, and Fanconi syndrome have been reported. Evaluate renal function prior to and during treatment; monitor urine for erythrocytes and signs of urotoxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancy: Secondary malignancies may occur (onset may be delayed); the risk for myelodysplastic syndrome (which may progress to acute leukemia) is increased with treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Wound healing: May interfere with wound healing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiation therapy: Use with caution in patients with prior radiation therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181823\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2B6 (major), CYP2C19 (minor), CYP2C8 (minor), CYP2C9 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181752\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13373&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of Ifosfamide. Specifically, concentrations of the toxic metabolites of ifosfamide may increase.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Busulfan: May enhance the adverse/toxic effect of Ifosfamide. Specifically, the risk of hemorrhagic cystitis may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2B6 Inducers (Moderate): May decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Ifosfamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease serum concentrations of the active metabolite(s) of Ifosfamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of Ifosfamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of Ifosfamide. Specifically, concentrations of the toxic metabolites of ifosfamide may increase.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP2B6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: May decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiotepa: May increase the serum concentration of CYP2B6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Ifosfamide may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181754\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4811888\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have been observed in animal reproduction studies. Fetal growth retardation and neonatal anemia have been reported with exposure to ifosfamide-containing regimens during human pregnancy. Male and female fertility may be affected (dose and duration dependent). Ifosfamide interferes with oogenesis and spermatogenesis; amenorrhea, azoospermia, and sterility have been reported and may be irreversible. Avoid pregnancy during treatment; male patients should not father a child during and for at least 6 months after completion of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047813\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential (prior to each dose), urine output, urinalysis (hematuria, prior to each dose), liver and renal function tests, serum electrolytes, CNS changes, signs and symptoms of pulmonary toxicity, signs and symptoms of hemorrhagic cystitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181746\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ifosfamide causes cross-linking of strands of DNA by binding with nucleic acids and other intracellular structures, resulting in cell death; inhibits protein synthesis and DNA synthesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181763\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;display:inline\">Pharmacokinetics are dose dependent </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Approximates total body water; penetrates CNS, but not in therapeutic levels </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Negligible </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to active metabolites isofosforamide mustard, 4-hydroxy-ifosfamide, acrolein, and inactive dichloroethylated and carboxy metabolites; acrolein is the agent implicated in development of hemorrhagic cystitis </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination (increased in the elderly): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">High dose (3,800 to 5,000 mg/m<sup>2</sup>): ~15 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lower dose (1,600 to 2,400 mg/m<sup>2</sup>): ~7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">High dose (5,000 mg/m<sup>2</sup>): Urine (70% to 86%; 61% as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lower dose (1,600 to 2,400 mg/m<sup>2</sup>): Urine (12% to 18% as unchanged drug)  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323192\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ifosfamide Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/20 mL (20 mL): $69.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 g/60 mL (60 mL): $129.05</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Ifex Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $79.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 g (1): $125.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Ifosfamide Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $44.09</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 g (1): $129.05</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181766\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alquimid (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Cuantil (AR, PY);</li>\n      <li>Farmamide (DE);</li>\n      <li>Fosfidex (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Holoksan (UA);</li>\n      <li>Holoxan (AE, AT, AU, BD, BE, BG, BH, CH, CL, CN, CY, CZ, DE, DK, EC, EE, EG, FI, FR, GR, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IS, IT, JO, KR, KW, LB, LT, LU, LV, LY, MT, MY, NL, NO, NZ, OM, PH, PK, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SY, TH, TR, TW, UY, VN, YE);</li>\n      <li>Holoxane (BR);</li>\n      <li>Ifadex (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Ifamide (BD);</li>\n      <li>Ifolem (MX);</li>\n      <li>Ifomida (MX);</li>\n      <li>Ifomide (JP);</li>\n      <li>Ifos (LB, PE, PY);</li>\n      <li>Ipamide (IN);</li>\n      <li>Iphox (PH);</li>\n      <li>Mitoxana (GB, IE);</li>\n      <li>Tolcamin (CO);</li>\n      <li>Tronoxal (ES);</li>\n      <li>Xifox (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abu-Ghosh AM, Krailo MD, Goldman SC, et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report. <i>Ann Oncol</i>. 2002;13(3):460-469.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/11996479/pubmed\" target=\"_blank\" id=\"11996479\">11996479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bacci G, Briccoli A, Rocca M, et al, &quot;Neoadjuvant Chemotherapy for Osteosarcoma of the Extremities With Metastases at Presentation: Recent Experience at the Rizzoli Institute in 57 Patients Treated With Cisplatin, Doxorubicin, and a High Dose of Methotrexate and Ifosfamide,&quot; <i>Ann Oncol</i>, 2003, 14(7):1126-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/12853357/pubmed\" target=\"_blank\" id=\"12853357\">12853357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baker KS, Anderson JR, Link MP, et al. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. <i>J Clin Oncol</i>. 2000;18(12):2427-2434.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/10856103/pubmed\" target=\"_blank\" id=\"10856103\">10856103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basaran M, Bavbek ES, Saglam S, et al, &quot;A Phase II Study of Cisplatin, Ifosfamide and Epirubicin Combination Chemotherapy in Adults With Nonmetastatic and Extremity Osteosarcomas,&quot; <i>Oncology</i>, 2007, 72(3-4):255-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/18185020/pubmed\" target=\"_blank\" id=\"18185020\">18185020</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Prestrud AA, Hesketh PJ, et al; American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2011;29(31):4189-4198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/21947834/pubmed\" target=\"_blank\" id=\"21947834\">21947834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cairo MS, Davenport V, Bessmertny O, et al, &quot;Phase I/II Dose Escalation Study of Recombinant Human Interleukin-11 Following Ifosfamide, Carboplatin and Etoposide in Children, Adolescents and Young Adults With Solid Tumours or Lymphoma: A Clinical, Haematological and Biological Study,&quot; <i>Br J Haematol</i>, 2005, 128(1):49-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/15606549/pubmed\" target=\"_blank\" id=\"15606549\">15606549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, &ldquo;Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients,&rdquo; <i>Pediatr Blood Cancer</i>, 2011, 57(2):191-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferrari A, De Salvo GL, Brennan B, et al. Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). <i>Ann Oncol</i>. 2015;26(3):567-572.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/25488687/pubmed\" target=\"_blank\" id=\"25488687\">25488687</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd J, Mirza I, Sachs B, et al, &quot;Hepatotoxicity of Chemotherapy,&quot; <i>Semin Oncol</i>, 2006, 33(1):50-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/16473644/pubmed\" target=\"_blank\" id=\"16473644\">16473644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gentet JC, Brunat-Mentigny M, Demaille MC, et al, &quot;Ifosfamide and Etoposide in Childhood Osteosarcoma. A Phase II Study of the French Society of Paediatric Oncology,&quot; <i>Eur J Cancer</i>, 1997, 33(2):232-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/9135494/pubmed\" target=\"_blank\" id=\"9135494\">9135494</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grier HE, Krailo MD, Tarbell NJ, et al, &quot;Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone,&quot;<i> N Engl J Med</i>, 2003, 348(8):694-701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/12594313/pubmed\" target=\"_blank\" id=\"12594313\">12594313</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griffin TC, Weitzman S, Weinstein H, et al, &quot;A Study of Rituximab and Ifosfamide, Carboplatin, and Etoposide Chemotherapy in Children With Recurrent/Refractory B-Cell (CD20+) Non-Hodgkin Lymphoma and Mature B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group,&quot; <i>Pediatr Blood Cancer</i>, 2009, 52(2):177-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/18816698/pubmed\" target=\"_blank\" id=\"18816698\">18816698</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Juergens C, Weston C, Lewis I, et al, &quot;Safety Assessment of Intensive Induction With Vincristine, Ifosfamide, Doxorubicin, and Etoposide (VIDE) in the Treatment of Ewing Tumors in the EURO-E.W.I.N.G. 99 Clinical Trial,&quot; <i>Pediatr Blood Cancer</i>, 2006, 47(1):22-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/16572419/pubmed\" target=\"_blank\" id=\"16572419\">16572419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE and Dorr RT, &quot;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&quot; <i>Cancer Treat Rev</i>, 1995, 21(1):33-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/7859226/pubmed\" target=\"_blank\" id=\"7859226\">7859226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kobrinsky NL, Sposto R, Shah NR, et al, &quot;Outcomes of Treatment of Children and Adolescents With Recurrent Non-Hodgkin's Lymphoma and Hodgkin's Disease With Dexamethasone, Etoposide, Cisplatin, Cytarabine, and l-Asparaginase, Maintenance Chemotherapy, and Transplantation: Children's Cancer Group Study CCG-5912,&quot;<i> J Clin Oncol</i>, 2001, 19(9):2390-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/11331317/pubmed\" target=\"_blank\" id=\"11331317\">11331317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kung FH, Pratt CB, Vega RA, et al. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. <i>Cancer</i>. 1993;71(5):1898-903.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/8448755/pubmed\" target=\"_blank\" id=\"8448755\">8448755</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kushner BH, Modak S, Kramer K, Basu EM, Roberts SS, Cheung NK. Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. <i>Cancer</i>. 2013;119(3):665-671.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/22951749/pubmed\" target=\"_blank\" id=\"22951749\">22951749</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Le Deley MC, Guinebreti&egrave;re JM, Gentet JC, et al, &quot;SFOP OS94: A Randomised Trial Comparing Preoperative High-Dose Methotrexate Plus Doxorubicin to High-Dose Methotrexate Plus Etoposide and Ifosfamide in Osteosarcoma Patients,&quot; <i>Eur J Cancer</i>, 2007, 43(4):752-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/17267204/pubmed\" target=\"_blank\" id=\"17267204\">17267204</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. <i>Lancet Oncol</i>. 2016;17(10):1396-1408.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/27569442/pubmed\" target=\"_blank\" id=\"27569442\">27569442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Milano GM, Cozza R, Ilari I, et al, &quot;High Histologic and Overall Response to Dose Intensification of Ifosfamide, Carboplatin, and Etoposide With Cyclophosphamide, Doxorubicin, and Vincristine in Patients With High-Risk Ewing Sarcoma Family Tumors: The Bambino Ges&ugrave; Children's Hospital Experience,&quot; <i>Cancer</i>, 2006, 106(8):1838-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/16532434/pubmed\" target=\"_blank\" id=\"16532434\">16532434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miser JS, Goldsby RE, Chen Z, et al. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children's Oncology Group. <i>Pediatr Blood Cancer</i>. 2007;49(7):894-900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/17584910/pubmed\" target=\"_blank\" id=\"17584910\">17584910</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miser JS, Kinsella TJ, Triche TJ, et al, &quot;Ifosfamide With Mesna Uroprotection and Etoposide: An Effective Regimen in the Treatment of Recurrent Sarcomas and Other Tumors of Children and Young Adults,&quot; <i>J Clin Oncol</i>, 1987, 5(8):1191-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/3114435/pubmed\" target=\"_blank\" id=\"3114435\">3114435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. <i>Blood</i>. 2001;97(3):616-623.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/11157476/pubmed\" target=\"_blank\" id=\"11157476\">11157476</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mu&ntilde;oz M, Girona V, Pujol M, Dur&aacute;n S, Vicente P, Sol&eacute; LA. Stability of ifosfamide in 0.9% sodium chloride solution or water for injection in a portable I.V. pump cassette. <i>Am J Hosp Pharm</i>. 1992;49(5):1137-1139.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/1595743/pubmed\" target=\"_blank\" id=\"1595743\">1595743</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oberlin O, Fawaz O, Rey A, et al, &quot;Long-Term Evaluation of Ifosfamide-Related Nephrotoxicity in Children,&quot; <i>J Clin Oncol</i>, 2009, 27(32):5350-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/19826134/pubmed\" target=\"_blank\" id=\"19826134\">19826134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paulussen M, Ahrens S, Dunst J, et al, &quot;Localized Ewing Tumor of Bone: Final Results of the Cooperative Ewing's Sarcoma Study CESS 86,&quot;<i> J Clin Oncol</i>, 2001, 19(6):1818-29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/11251014/pubmed\" target=\"_blank\" id=\"11251014\">11251014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paulussen M, Craft AW, Lewis I, et al, &quot;Results of the EICESS-92 Study: Two Randomized Trials of Ewing's Sarcoma Treatment - Cyclophosphamide Compared With Ifosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk Patients,&quot;<i> J Clin Oncol</i>, 2008, 26(27):4385-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/18802150/pubmed\" target=\"_blank\" id=\"18802150\">18802150</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Herrstedt J, Aapro M, et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. <i>Ann Oncol</i>. 2010;21(suppl 5):v232-v243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/20555089/pubmed\" target=\"_blank\" id=\"20555089\">20555089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandlund JT, Pui CH, Mahmoud H, et al, &quot;Efficacy of High-Dose Methotrexate, Ifosfamide, Etoposide and Dexamethasone Salvage Therapy for Recurrent or Refractory Childhood Malignant Lymphoma,&quot; <i>Ann Oncol</i>, 2011, 22(2):468-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/20624787/pubmed\" target=\"_blank\" id=\"20624787\">20624787</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Winkle P, Angiolillo A, Krailo M, et al, &quot;Ifosfamide, Carboplatin, and Etoposide (ICE) Reinduction Chemotherapy in a Large Cohort of Children and Adolescents With Recurrent/Refractory Sarcoma: The Children's Cancer Group (CCG) Experience,&quot; <i>Pediatr Blood Cancer</i>, 2005, 44(4):338-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/15503297/pubmed\" target=\"_blank\" id=\"15503297\">15503297</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weigel BJ, Lyden E, Anderson JR, et al. Intensive multiagent therapy, tncluding dose-compressed cycles of ifosfamide/etoposide and vincristine/doxorubicin/cyclophosphamide, irinotecan, and radiation, in patients with high-risk rhabdomyosarcoma: a report from the Children's Oncology Group. <i>J Clin Oncol</i>. 2016;34(2):117-122.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ifosfamide-pediatric-drug-information/abstract-text/26503200/pubmed\" target=\"_blank\" id=\"26503200\">26503200</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13373 Version 154.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708917\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F181779\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F181780\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1047814\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1047806\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F181758\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F181743\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1047818\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132621\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F181773\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1047817\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2136825\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F181833\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F181764\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F181747\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F181823\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F181752\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F181754\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F4811888\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1047813\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F181746\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F181763\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323192\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F181766\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13373|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ifosfamide-drug-information\" class=\"drug drug_general\">Ifosfamide: Drug information</a></li><li><a href=\"topic.htm?path=ifosfamide-patient-drug-information\" class=\"drug drug_patient\">Ifosfamide: Patient drug information</a></li></ul></div></div>","javascript":null}